sb 202190 has been researched along with Reperfusion Injury in 2 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Tian, FZ | 1 |
| Tang, LJ | 1 |
| Shi, L | 1 |
| Zhang, XQ | 1 |
| Prakash, J | 1 |
| Sandovici, M | 1 |
| Saluja, V | 1 |
| Lacombe, M | 1 |
| Schaapveld, RQ | 1 |
| de Borst, MH | 1 |
| van Goor, H | 1 |
| Henning, RH | 1 |
| Proost, JH | 1 |
| Moolenaar, F | 1 |
| Këri, G | 1 |
| Meijer, DK | 1 |
| Poelstra, K | 1 |
| Kok, RJ | 1 |
2 other studies available for sb 202190 and Reperfusion Injury
| Article | Year |
|---|---|
[The role of p38 MAPK pathway in ischemia-reperfusion injury of isolated liver].
Topics: Animals; Enzyme Inhibitors; Female; Hepatocytes; Imidazoles; In Vitro Techniques; Liver; Male; p38 M | 2003 |
Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis.
Topics: Animals; Biological Transport; Cisplatin; Fibrosis; Imidazoles; Kidney; Kidney Tubules, Proximal; Ma | 2006 |